Dr. Nicholas Martinez, M.D
NPI: 1174843726
Total Payments
$141,145
2024 Payments
$39,295
Companies
47
Transactions
665
Medicare Patients
3,003
Medicare Billing
$422,543
Payment Breakdown by Category
Research$69,389 (49.2%)
Other$52,230 (37.0%)
Food & Beverage$12,581 (8.9%)
Travel$4,615 (3.3%)
Consulting$2,300 (1.6%)
Education$30.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $69,389 | 13 | 49.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,830 | 21 | 33.2% |
| Food and Beverage | $12,581 | 605 | 8.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,400 | 2 | 3.8% |
| Travel and Lodging | $4,615 | 20 | 3.3% |
| Consulting Fee | $2,300 | 2 | 1.6% |
| Education | $30.31 | 2 | 0.0% |
Payments by Type
General
$71,756
652 transactions
Research
$69,389
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | $38,278 | 56 | $0 (2024) |
| Bausch Health US, LLC | $36,686 | 2 | $0 (2020) |
| Eli Lilly and Company | $32,759 | 13 | $0 (2023) |
| Amgen Inc. | $12,172 | 8 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $7,453 | 67 | $0 (2024) |
| Romark Laboratories, LC | $4,945 | 11 | $0 (2020) |
| ABBVIE INC. | $2,808 | 187 | $0 (2024) |
| Janssen Biotech, Inc. | $1,222 | 103 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $941.36 | 8 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $787.47 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,295 | 115 | Phathom Pharmaceuticals, Inc. ($38,278) |
| 2023 | $2,064 | 58 | Eli Lilly and Company ($976.70) |
| 2022 | $1,396 | 81 | ABBVIE INC. ($696.11) |
| 2021 | $31,830 | 72 | Eli Lilly and Company ($18,697) |
| 2020 | $15,991 | 53 | Bausch Health US, LLC ($12,765) |
| 2019 | $33,795 | 102 | Bausch Health US, LLC ($23,921) |
| 2018 | $13,000 | 113 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($6,653) |
| 2017 | $3,775 | 71 | Romark Laboratories, LC ($2,350) |
All Payment Transactions
665 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.24 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,720.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.69 | General |
| Category: Immunology | ||||||
| 11/12/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/08/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Immunology | ||||||
| 10/29/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Hematology | ||||||
| 10/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $18.13 | General |
| 10/14/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $8.07 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/09/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.21 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $116.99 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Gastroenterology | ||||||
| 09/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: IMMUNOLOGY | ||||||
| 09/11/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Immunology | ||||||
| 09/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,010.00 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOME PRO MEASURE FOR SMALL INTESTINAL BACTERIAL OVERGROWTH SIBO | Bausch Health US, LLC | $23,921 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $20,531 | 3 |
| DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOME (PRO) MEASURE FOR SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) | Bausch Health US, LLC | $12,765 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $6,094 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $4,135 | 4 |
| A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | Eli Lilly and Company | $976.70 | 1 |
| AN ADAPTIVE PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LY3471851 (NKTR 358) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $966.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 684 | 1,235 | $325,265 | $94,200 |
| 2022 | 13 | 703 | 1,303 | $320,150 | $105,119 |
| 2021 | 18 | 885 | 1,555 | $407,380 | $122,136 |
| 2020 | 17 | 731 | 1,291 | $336,515 | $101,088 |
Total Patients
3,003
Total Services
5,384
Medicare Billing
$422,543
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 227 | 508 | $76,200 | $44,425 | 58.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 156 | $17,160 | $9,305 | 54.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 55 | 55 | $53,350 | $6,686 | 12.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 63 | $12,915 | $6,195 | 48.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $10,500 | $5,110 | 48.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 57 | 182 | $22,750 | $4,483 | 19.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 74 | 76 | $55,860 | $4,210 | 7.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 25 | 25 | $22,000 | $3,187 | 14.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 22 | $4,730 | $2,900 | 61.3% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 15 | 15 | $19,050 | $2,148 | 11.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 18 | 21 | $13,335 | $1,572 | 11.8% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 29 | 31 | $3,565 | $1,502 | 42.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 15 | 17 | $2,160 | $1,318 | 61.0% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 14 | 14 | $11,690 | $1,160 | 9.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 245 | 558 | $83,700 | $51,021 | 61.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 73 | 235 | $25,850 | $12,592 | 48.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $14,715 | $7,603 | 51.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 67 | 74 | $15,170 | $7,327 | 48.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 52 | 52 | $50,440 | $6,424 | 12.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 62 | 64 | $47,040 | $4,089 | 8.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 39 | 136 | $17,000 | $3,504 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 25 | $5,375 | $3,342 | 62.2% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2022 | 19 | 21 | $26,670 | $3,075 | 11.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 17 | 17 | $14,960 | $2,150 | 14.4% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $12,120 | $1,652 | 13.6% |
About Dr. Nicholas Martinez, M.D
Dr. Nicholas Martinez, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2010. The National Provider Identifier (NPI) number assigned to this provider is 1174843726.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Martinez, M.D has received a total of $141,145 in payments from pharmaceutical and medical device companies, with $39,295 received in 2024. These payments were reported across 665 transactions from 47 companies. The most common payment nature is "" ($69,389).
As a Medicare-enrolled provider, Martinez has provided services to 3,003 Medicare beneficiaries, totaling 5,384 services with total Medicare billing of $422,543. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Gastroenterology
- Location San Antonio, TX
- Active Since 06/06/2010
- Last Updated 07/19/2016
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1174843726
Products in Payments
- XIFAXAN (Drug) $41,437
- VOQUEZNA (Drug) $38,278
- AVSOLA (Biological) $12,172
- Alinia Tablets 500mg 30 count bottle (Drug) $3,773
- STELARA (Biological) $2,020
- Alinia (Drug) $1,135
- RINVOQ (Biological) $715.17
- HUMIRA (Biological) $532.46
- LINZESS (Drug) $501.24
- Cimzia (Drug) $439.29
- Humira (Biological) $356.08
- GATTEX (Drug) $355.31
- SKYRIZI (Biological) $317.69
- TRULANCE (Drug) $302.15
- CREON (Drug) $301.93
- XELJANZ (Drug) $237.53
- ZEPOSIA (Drug) $185.65
- Entyvio (Biological) $182.26
- Creon (Drug) $165.62
- ESD (Device) $149.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in San Antonio
Annabelle Garcia, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $200,714
Student in an Organized Health Care Education/Training Program $200,714
Dr. Marvin Eng, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $153,111
Student in an Organized Health Care Education/Training Program $153,111
Dr. Russell Higgins, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $42,909
Student in an Organized Health Care Education/Training Program $42,909
Dr. Thomas Gianis, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $21,470
Student in an Organized Health Care Education/Training Program $21,470
Dr. Salim Rezaie
Student in an Organized Health Care Education/Training Program — Payments: $21,063
Student in an Organized Health Care Education/Training Program $21,063
Dr. Tessa Cervantes, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $19,498
Student in an Organized Health Care Education/Training Program $19,498